Clinical trial
A Single Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of Once Daily 25mg Empagliflozin in Patients on Peritoneal Dialysis With Residual Kidney Function
NCT05715814 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of Once Daily 25mg Empagliflozin in Patients on Peritoneal Dialysis With Residual Kidney Function
- Lead sponsor
- University Health Network, Toronto
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 1, 2024
- Completion date
- December 1, 2027
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
end stage kidney disease, kidney dysfunction, peritoneal dialysis complication, residual kidney function, sodium-glucose co-transporter-2 inhibitors